Pharma patents and Article 31bis: where are we now?

In December 2005 this decision was replaced by a fresh one, which would amend TRIPS itself once accepted by two thirds of the TRIPS membership, enacting a new Article 31bis that would formally legitimise the Doha principle while retaining the notification system.
The IPKat recalls that European Union law is itself Doha-compliant. He also understands that the deadline for getting the two-thirds signed up is 31 December 2009, which is only a few short months away. What's the current state of play, he wonders? Can any reader advise?